Treatment of female sexual dysfunction using phosphodiesterase inhibitors
US6469016B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2000 |
| Grant date | Oct 22, 2002 |
| Priority date | — |
| Expiry date | Feb 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.